CV toxicity, especially hypertension, is the most frequent event in patients with RR‐DTC treated with MKI‐targeting VEGFR, and the risk is greater in those with a history of CVD, CV risk factors, or previous hypertension. This evidence concerns the gene KDR and Hypertension.